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Abstract
Background: Early diagnosis of tuberculosis (TB) and multidrug resistant tuberculosis (MDR TB) is important for the
elimination of TB. We evaluated the microscopic observation drug susceptibility (MODS) assay as a direct rapid
drug susceptibility testing (DST) method for MDR-TB screening in sputum samples
Methods: All adult TB suspects, who were newly presenting to Pham Ngoc Thach Hospital from August to
November 2008 were enrolled into the study. Processed sputum samples were used for DST by MODS (DST-
MODS) (Rifampicin (RIF) 1 μg/ml and Isoniazid (INH) 0.4 μg/ml), MGIT culture (Mycobacterial Growth Indicator Tube)
and Lowenstein Jensen (LJ) culture. Cultures positive by either MGIT or LJ were used for proportional DST (DST-LJ)
(RIF 40 μg/ml and INH 0.2 μg/ml). DST profiles on MODS and LJ were compared. Discrepant results were resolved
by multiplex allele specific PCR (MAS-PCR).
Results: Seven hundred and nine TB suspects/samples were enrolled into the study, of which 300 samples with
DST profiles available from both MODS and DST-LJ were analyzed. Cording in MODS was unable to correctly
identify 3 Mycobacteria Other Than Tuberculosis (MOTT) isolates, resulting in 3 false positive TB diagnoses. None of
these isolates were identified as MDR-TB by MODS. The sensitivity and specificity of MODS were 72.6% (95%CI: 59.8,
83.1) and 97.9% (95%CI: 95.2, 99.3), respectively for detection of INH resistant isolates, 72.7% (95%CI: 30.9, 93.7) and
99.7% (95%CI: 98.1, 99.9), respectively for detecting RIF resistant isolates and 77.8% (95%CI: 39.9, 97.1) and 99.7%
(95%CI: 98.1, 99.9), respectively for detecting MDR isolates. The positive and negative predictive values (PPV and
NPV) of DST-MODS were 87.5% (95%CI: 47.3, 99.6) and 99.3% (95%CI: 97.5, 99.9) for detection of MDR isolates; and
the agreement between MODS and DST-LJ was 99.0% (kappa: 0.8, P < 0.001) for MDR diagnosis. The low sensitivity
of MODS for drug resistance detection was probably due to low bacterial load samples and the high INH
concentration (0.4 μg/ml). The low PPV of DST-MODS may be due to the low MDR-TB rate in the study population
(3.8%). The turnaround time of DST-MODS was 9 days and 53 days for DST-LJ.
Conclusion: The DST-MODS technique is rapid with low contamination rates. However, the sensitivity of DST-
MODS for detection of INH and RIF resistance in this study was lower than reported from other settings.
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The worldwide occurrence of multidrug-resistant tubercu-
losis (MDR-TB) has been documented by the World
Health Organization (WHO), with estimates of nearly half
a million cases annually, and 150,000 deaths [1]. MDR-TB
is caused by Mycobacterium tuberculosis (M. tuberculosis)
which is resistant to at least the two most powerful TB
drugs isoniazid (INH) and rifampicin (RIF). In addition to
the high costs, long duration of treatment and the lack of
randomized controlled trials for optimal regimens, a major
barrier to control of MDR TB is the lack of laboratory
diagnostic capacity in high-TB burden settings. Major
initiatives are now under way to scale-up capacity for both
M. tuberculosis culture and drug susceptibility testing
(DST) [2]. According to WHO, of 27 high MDR-TB bur-
den countries, only 22 countries had a National Reference
Laboratory in 2008. Of 572 laboratories performing drug
susceptibility testing (DST), only half participated in exter-
nal quality assurance [1].
Recently, the documentation in over 50 countries of
extensively drug-resistant tuberculosis (XDR-TB),
defined as MDR-TB plus resistance to a fluoroquinolone
and at least one second-line injectable agent (amikacin,
kanamycin or capreomycin) [1] has further emphasized
the need to scale up detection and treatment of MDR
TB. In HIV co-infected individuals the classical smear
diagnostic test has very low sensitivity and the need for
enhanced culture has further urgency in settings with
HIV co-epidemics; late diagnosis and treatment contri-
butes to high mortality rates and on-going transmission
in this population [3]. Classical DST for M. tuberculosis
on solid media requires 6-8 weeks as the sputum sample
must first be cultured and then regrown on drug-con-
taining media. In 2007, WHO recommended the use of
liquid culture and DST in low and middle-income coun-
tries as a step-wise approach to scale up TB and MDR-
TB diagnosis and management [4,5]. Automated liquid
culture allows turn-around times of 20-28 days when
indirect DST is performed but the automated equipment
is expensive for most high-burden settings and cheaper
alternative methods may be easier to implement. Other
phenotypic techniques have been also been developed.
Nitrate reductase assay (NRA), a solid media DST techni-
que which is based on the ability of M. tuberculosis to
reduce nitrate to nitrite has also been endorsed by WHO
[6,7]. Although NRA can be performed on both culture
isolates and specimens, more evidence is required regard-
ing the accuracy of NRA applied directly on specimens.
Colorimetric methods are based on the reduction of an
indicator dye which is added to the culture medium after
M. tuberculosis has been inoculated with or without anti-
biotics. The growth of a resistant isolate is detected by a
change in colour of the indicator, which is directly
proportional to the number of viable mycobacteria in the
medium. A review of published data concluded that the
sensitivity and specificity of this method are 89% and
100%, respectively, and the result is available in 7-14 days
[7]. However, colorimetric assays are performed on cul-
ture isolates so a primary isolation is needed which takes
approximately 2-4 weeks. The Thin Layer Agar (TLA)
assay has also shown promise with for detection of RIF
and INH resistant isolates [8], however the WHO strate-
gic technical advisory group (STAG) concluded that
there is currently insufficient evidence to recommend the
use of TLA for MDR-TB detection and further evaluation
is required [6].
Molecular line probe assays (LPA) for rapid detection of
MDR-TB, which are based on reverse hybridization tech-
nology have been endorsed by WHO in 2009 [9]. With
sensitivity and specificity of over 90% and 99%, respec-
tively against the conventional DST method [10], LPA are
an alternative rapid and accurate DST method but are
only reliable in smear positive cases. Unfortunately, the
cost and the requirement for relatively complicated tech-
nology and infrastructure in addition to well-trained staff
have limited the use of LPA in high TB burden countries
where the need is greatest. Xpert MTB/RIF (Cepheid,
USA), is a novel real-time PCR based technique which
detects M. tuberculosis and rifampicin resistance muta-
tions directly from sputum samples. In evaluations in
South Africa, the test showed sensitivity and specificity for
M. tuberculosis detection of 98% and 99%, respectively and
correctly identified 97.6% isolates with RIF resistant iso-
lates and 98% of rifampicin susceptible isolates compared
with phenotypic DST [11]. However, some false-positive
RIF resistance results were initially reported [11,12]. The
Ct ratio threshold has been revised but it is not yet clear if
this has eliminated false-positive results for RIF resistance.
Furthermore, the cost remains relatively high for use in
developing countries at the present time, with FIND nego-
tiated pricing of 18USD per test cartridge [13]. Therefore,
no single test currently available provides all the character-
istics of an ideal test for rapid diagnosis of MDR-TB,
which would be rapid, low-cost, easy to perform, and
highly sensitive and specific. Microscopic Observation
Drug Susceptibility (MODS) assay, is a direct rapid DST
test which has been evaluated for MDR screening from
clinical specimens. Previous studies have shown it an accu-
rate, feasible and low-cost test that is promising for use in
high burden countries for early diagnosis of MDR TB
[14-16]. Procedures for quality assurance of the test are
still in development [17] and the accuracy of the test when
adopted by non-expert groups needs to be confirmed [18].
This technique is now endorsed by WHO for use in
resource-limited settings as an interim solution to increase
TB case detection [6,9].
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Page 2 of 11Viet Nam is a high TB burden country with steeply ris-
ing rate of HIV-TB co-infection [19]; 8% of newly diag-
nosed TB patients in 2007 were HIV infected [20]. The
prevalence of MDR-TB among new TB cases and retreat-
ment cases in 2007 were 2.7% and 19%, respectively.
Importantly, XDR-TB has been detected in Viet Nam [21].
These MDR-TB and XDR-TB cases are the most urgently
in need of diagnosis because they have the highest mor-
bidity and mortality yet effective diagnosis is not widely
available. We conducted a study to evaluate the accuracy
of MODS in early diagnosis of MDR-TB in new TB sus-
pects in Viet Nam.
Methods
Enrollment
All patients suspected of tuberculosis, who were newly
presenting to the Out Patient Department (OPD) at Pham
Ngoc Thach Hospital from August to November 2008
were enrolled into the study. Exclusion criteria were an
age < 16 years of age or a prior dose of TB therapy.
Data on demographic features, TB history and HIV sta-
tus were prospectively collected on a standard case report
form. Samples were collected as per routine care as
deemed appropriate by the treating physician. No addi-
tional samples were collected as part of this study and
only the first sputum sample of each patient was
evaluated.
Ethics
The protocol was approved by the Institutional Review
Board (IRB) at Pham Ngoc Thach Hospital and the Health
Services of Ho Chi Minh City. Individual informed con-
sent was not sought because the study was conducted on
routine samples only and it did not involve any interven-
tion, additional samples or change in patient management.
A patient consent waiver was approved by the IRB of
Pham Ngoc Thach Hospital.
Sample processing
Sputum samples were homogenised and decontaminated
by Sputaprep (NaOH-NALC 2%) manufactured by Nam
Khoa Company, Viet Nam prior to testing, as previously
described [22]. The processed sample was aliquoted into 3
parts for direct DST by MODS, MGIT culture and LJ cul-
ture. A positive MGIT or positive LJ culture from each
sample was used for 1% proportional DST method (indir-
ect DST method).
Direct DST by MODS (DST-MODS)
For each processed sample, 2 drug-free wells (control
wells), 1 INH containing well and 1 RIF containing well
were set up. In brief, the MODS media was prepared with
5.9 g Middlebrook 7H9 broth (Difco, Sparks, MD), 3.1 ml
glycerol and 1.25 g bacto casitione (Difco, USA) in 880 ml
distilled water. This media was autoclaved, filtered and
stored in 4.5 ml tubes at 4°C. Each new batch of media
was tested for sterility by incubating one aliquot at 37°C
for 1 week. Before use, 0.5 ml OADC (BD), 0.5 ml pro-
cessed sample and 100 μl PANTA antibiotic (BD) were
added into each 4.5 ml tube. Nine hundred microlitres of
the suspension was then transferred to each of four wells
in a 48 well-plate as described above. Next, 100 μl distilled
water was added into the control wells. Finally, 100 μl
INH 4 μg/ml (Sigma) or 100 μl RIF 10 μg/ml (Sigma) was
added to the INH-containing well and RIF-containing
well, respectively. The final concentrations of OADC and
PANTA in each well were 10% and 20 μl/ml, respectively.
The drug concentrations in each well were 0.4 μg/ml for
INH and 1 μg/ml for RIF. One susceptible isolate
(H37Rv), one INH-resistant clinical isolate and one RIF-
resistant clinical isolate were inoculated to the first plate
each day. Resistant control isolates are well-characterised
clinical isolates from Pham Ngoc Thach laboratory used
as routine controls for all DST procedures. A McFarland
0.5 (approximately 10
4 CFU/ml) suspension of each isolate
was made and diluted 100-fold (10
2 CFU/ml). A 0.5 ml
volume of the final suspension was used as the inoculum.
The plate was incubated at 37°C, and the results were
recorded on alternate days from day 5 to day 15 and twice
a week from day 16 to 1 month. Any cord formation in at
least one control well was recorded as a positive MODS
culture. If there was any cord formation in both control
wells, the drug containing wells were read. If cords were
detected in only one control well, MODS-DST was
recorded as uninterpretable for technical analysis. Any iso-
late with growth in both the control and drug-containing
wells was recorded as resistant. If growth was observed in
control wells but not in the drug-containing wells, a sus-
ceptible result was recorded for the relevant drug.
MGIT culture
All processed samples were aliquoted for MGIT culture
following the protocol of Becton Dickinson (BACTEC™
MGIT™ 960 Mycobacerial Detection System) [23].
Lowenstein-Jensen culture (LJ culture)
All processed samples were cultured on LJ. One hun-
dred microlitres of processed sample was inoculated
onto a LJ slant and incubated at 37°C. Results were read
weekly from day 21 after inoculation following routine
standard operating procedure of Pham Ngoc Thach hos-
pital. The presence of at least one colony with rough
shape was recorded as positive culture.
Subculture on LJ
All cultures positive by MGIT or LJ were subcultured
on LJ (Becton Dickinson) for indirect DST, standard
biochemical identification (Niacin and Nitrate) and
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Page 3 of 11archiving [24]. Mycobacteria Other Than Tuberculosis
(MOTT) identified by biochemical tests were confirmed
by LiPA MYCOBACTERIA assay (Innogenetics,
Belgium).
All cultures positive by MODS (control wells) were
subcultured on LJ in duplicate for DNA extraction [25]
and archiving [24].
If DNA extraction from MODS isolates failed due to
contamination or failure to grow on subculture, DNA
extraction from positive MGIT or LJ was performed, if
available.
Indirect DST test-1% proportional DST method (DST-LJ)
Indirect phenotypic DST method was performed at the
R e f e r e n c eT Bl a b o r a t o r ya tP h a mN g o cT h a c hH o s p i -
tal, which is accredited by the WHO reference TB
laboratory of Western Pacific region (Adelaide, Austra-
lia). Indirect DST was performed for all positive MGIT
or LJ isolates on Isoniazid 0.2 μg/ml, Streptomycin
4 μg/ml, Rifampicin 40 μg/ml, Ethambutol 2 μg/ml
and Pyrazinamide 200 μg/ml according to WHO
guidelines [26].
Multiplex Allele Specific PCR (MAS-PCR) for detection of
Isoniazid and Rifampicin resistance mutations
MAS-PCR was performed as previously described to
detect mutations in the Rifampicin Resistance Determin-
ing Region (RRDR) of the rpoB gene at codons 516
(D516V/A/G), 526 (H526D/F/L/R/S/Y/Q/N) and 531
(S531L) [27] and mutations in katG (S315T) and inhA
(C-15 T) genes for INH resistance [28].
The RRDR region of rpoB was sequenced for RIF-dis-
crepant isolates with no RRDR mutation identified by
MAS-PCR [27].
In this study, MAS-PCR was used to confirm INH and
RIF resistance in isolates classified as susceptible by
MODS and resistant by LJ, or vice versa. MAS-PCR
cannot be used to ‘rule-out’ true resistance because
approximately 5% and 20% of RIF and INH resistant
isolates, respectively will not have mutations in the tar-
geted gene sites [29].
Spoligotyping
Spoligotyping was performed according to the standard
international Spoligotyping protocol [7] for all cultures
positive by MODS (n = 329). If MODS was contami-
nated during subculture from MODS to LJ for DNA
extraction (n = 24) or MODS was negative but MGIT
positive (n = 36), cultures positive by MGIT were used
for spoligotyping. Spoligotyping was used to support the
screening of cross-contamination (data not shown).
Cross-contamination of MGIT was not addressed in this
study due to resource limitations.
Statistics
Detection rates for MODS, MGIT and LJ were summar-
ized and compared between methods using McNemar’s
test. The accuracy of MODS for diagnosis of TB was then
assessed using MGIT and LJ as the gold-standard refer-
ence test, i.e. a sample was defined as positive by the refer-
ence test if either MGIT or LJ (or both) were positive. The
accuracy of MODS for drug-susceptibility testing was
assessed in samples with a valid drug susceptibility test
result by both MODS and DST-LJ. The gold-standard
reference test was the DST-LJ result. We also summarized
agreement between DST-MODS and DST-LJ as raw
agreement and by Cohen’s kappa. Confidence intervals for
accuracy measures (sensitivities, specificities, positive and
negative predictive values) were calculated according to
the method of Pearson and Clopper. Finally, we compared
the time to a positive test for MGIT and MODS, respec-
tively, in samples positive by both methods using the
Wilcoxon signed rank test and visualized it using the
empirical cumulative distribution.
All reported confidence interval are two-sided 95% con-
fidence intervals and p-values ≤ 0.05 were regarded as sta-
tistically significant. All analyses and graph were
performed with Stata version 9 (Statacorp, Texas, USA).
Cross-contamination was investigated using spoligotyp-
ing. Identification of H37Rv from any well except the posi-
tive control well was considered as a cross-contamination
event. Cross contamination was suspected if at least one
control well was positive by DST-MODS and both MGIT
and LJ culture were negative for that sample. In these
cases if spoligotyping showed the isolate was unique on
the MODS plate processed that day, contamination was
discounted. If the isolate showed a spoligotype identical to
another isolate on the same plate, contamination could
not be ruled-out and we therefore report the maximum
possible cross-contamination rate.
Results
Study population and demography
Seven-hundred and nine patients clinically suspected of
tuberculosis were enrolled into the study. The median
age was 39 years (IQR: 27-53 years). The male:female
ratio was 1.7 (n = 447/262). HIV status was unknown
for the majority of the patients (99.0%, n = 702/709)
and only one patient was recorded as HIV positive.
Accuracy of MODS culture for M. tuberculosis detection
against MGIT culture or LJ culture as the gold standard
In 709 sputum samples sent for TB diagnosis, the detec-
tion rates of MODS, MGIT and LJ were 50.5% (n =
358/709, 95%CI: 46.7, 54.2), 51.6% (n = 366/709, 95%CI:
47.9, 55.3) and 44.4% (n = 315/709, 95%CI: 40.7, 48.1),
respectively. No significant differences in detection rates
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MODS and LJ (P = 0.17) or MGIT and LJ (P = 0.11).
There were 373/709 (52.6%) samples positive by either
MGIT or LJ culture. The accuracy of MODS in diagno-
sis of TB is presented in Table 1.
Detection of drug-resistance
Drug-resistant isolates detected by 1% proportion method
(DST-LJ-the gold standard method) (n = 364)
Although there were 373 samples positive by either MGIT
or LJ, 9 samples were initially identified as MOTT by bio-
chemical identification tests (3 M. fortuitum,3M. chelo-
nae and 3 unspeciated MOTT) and therefore DST-LJ was
not done for these samples. Of these 9 samples, one sam-
ple was MODS negative, one sample was contaminated by
fungi on MODS culture and seven samples were culture
positive by MODS but could not be differentiated from
M. tuberculosis complex by cording observation. We sub-
sequently performed the LiPA MYCOBACTERIA assay
for the remaining seven isolates. The line probe assay
identified four of these isolates as M. tuberculosis,a l lo f
which were susceptible to both RIF and INH by MODS-
DST. The remaining three isolates were identified as
M. kansasii, M. chelonae (both susceptible to RIF but
resistant to INH by MODS) and M. fortuitum (susceptible
to both RIF and INH by MODS). As a result, 364/373
samples with DST results by 1% proportion method were
available for analysis. The multidrug resistant isolates
(MDR-TB) account for 3.8% (n = 14/364) of cases. Isonia-
zid and Rifampicin monoresistance were detected in 3.8%
(n = 14/364) and 0.3% (n = 1/364) of samples, respectively.
Study population for the evaluation of DST-MODS
Of the 358 samples positive by MODS culture, 88.5%
(n = 317/358) had two control wells (drug-free wells)
positive by DST-MODS and 94.6% (n = 300/317) of
them were eligible for final DST analysis between DST-
MODS and DST-LJ (Figure 1). 5.4% (n = 17/317)
samples were excluded from analysis because of prob-
able cross-contamination by MODS (n = 1) and no
DST-LJ results (n = 16). The remaining positive MODS
samples (11.5%, n = 41/358) only had one control well
positive by MODS and were analyzed separately.
DST-MODS analysis (n = 300)
DST-MODS against DST-LJ as the gold standard
Direct drug susceptibility testing results on MODS were
compared with indirect DST on LJ as the gold standard
for 300 samples (Figure 2). DST-MODS detected INH,
RIF and MDR resistant isolates at 16.7% (n = 50/300), 3%
(n = 9/300) and 2.7% (n = 8/300), respectively. The accu-
racy of MODS in detection of INH and/or RIF resistant
isolates is shown in Table 1. The agreement between
DST-MODS and DST-LJ were 92.7% (n = 278/300, 95%
CI: 89.1, 95.3, kappa: 0.75, P < 0.001) for detection of INH
resistant isolates, 98.7% (n = 296/300, 95%CI: 96.6, 99.6,
kappa: 0.79, P < 0.001) for RIF resistant isolates and 99%
(n = 297/300, 95%CI: 97.1, 99.7, kappa: 0.80, P < 0.001) for
detection of MDR isolates.
Resolution of discrepant results
There was 25/300 isolates with discrepant DST results
between MODS and LJ for INH, RIF or both INH and RIF
(Table 2). Of which, 3 samples were discrepant for RIF
resistance only, 21 samples were discrepant for INH resis-
tance only and 1 sample was discrepant for both INH and
RIF resistance.
Among four isolates with RIF results discrepant
between DST-MODS and DST-LJ (Table 2), repeated
DST-MODS for RIF 1 μg/ml, MAS-PCR and rpoB
sequencing confirmed RIF resistance for one isolate (iso-
lates 4, Table 2) and RIF susceptible for three isolates
(isolates 1,2,3) (Table 2).
There were two MDR isolates identified by LJ but not by
MODS (both isolates were INH resistant and RIF suscepti-
b l eb yM O D S ,T a b l e2 ,i s o l a t e s2 , 4 )w e r er e s o l v e db y
MAS-PCR. Of these two isolates, one isolate was
Table 1 Sensitivity, specificity, positive predictive value and negative predictive value of MODS in detection of M.
tuberculosis and INH or RIF resistance
Sensitivity
% (n = x/y) 95%CI
Specificity
% (n = x/y) 95%CI
PPV
% (n = x/y) 95%CI
NPV
% (n = x/y) 95%CI
MODS diagnosis of TB 89.0 (332/373) [85.4,
91.9]
92.3 (310/336) [88.9,
94.9]
92.7 (332/358) [89.5,
91.5]
88.3 (310/351) [84.5,
91.5]
MODS for detection of INH resistant
isolates
72.6 (45/62) [59.8, 83.1] 97.9 (233/238) [95.2,
99.3]
90.0 (45/50) [78.2, 96.7] 93.2 (233/250) [89.3,
95.9]
MODS for detection of RIF resistant
isolates
72.7 (8/11) [39.0, 93.9] 99.7 (288/289) [98.1,
99.9]
88.9 (8/9)
[51.8, 99.7]
98.9 (290/292) [97.5,
99.9]
MODS for detection of MDR isolates 77.8 (7/9)
[39.9, 97.1]
99.7 (290/291) [98.1,
99.6]
87.5 (7/8)
[47.3, 99.6]
99.3 (290/292) [97.5,
99.9]
PPV: Positive predictive value
NPV: Negative predictive value
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isolate failed to amplify and rpoB identified only a synon-
ymous mutation in this gene.
There was one MDR isolate identified by DST-MODS
which was INH and RIF susceptible by DST-LJ (Table 2,
isolate 1). MAS-PCR detected an INH resistance
Figure 1 Recruitment flow chart. MOTT: Mycobacteria Other Than Tuberculosis. DST-MODS: Drug susceptibility testing done by MODS. DST-LJ:
Drug susceptibility testing done by 1% proportional method on LJ media. (*) Analysis based on DST/LJ and MAS-PCR because DST/MODS
results were recorded as uninterpretable
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Page 6 of 11Figure 2 Drug susceptibility testing results of 300 isolates by MODS and LJ for Rifampicin and Isoniazid. RIF: Rifampicin, INH: Isoniazid,
LJ: proportional DST method on LJ medium, MODS: microscopic observation drug susceptibility assay
Table 2 Discrepant DST results between MODS and LJ resolved by MAS-PCR
Isolate
N0
DST-MODS DST-LJ MAS-PCR (mutation point) Remarks
RIF 1
μg/ml
INH 0.4
μg/ml
RIF 40
μg/ml
INH 0.2
μg/ml
RIF resistant
mutation
INH resistant
mutation
1 R R S S None R (katG) MDR by MODS
2 S R R R _ RIF-MODS resistant on day 20. MDR by LJ.
rpoB sequencing: synonymous mutation
(H445C, CAC > TGC)
3 S S R S None None
4 S R R R R (531) RIF-MODS resistant on day 20. MDR by LJ
5 S R S S None
6 S R S S None
7 S R S S None
8 S R S S None
9 S S S R R (katG) INH-MODS resistant on day 30
10 S S S R None INH-MODS resistant on day 30
11 S S S R R (katG) INH-MODS resistant on day 40
12 S S S R R (inhA)
13 S S S R R (inhA)
14 S S S R R (inhA)
15 S S S R R (katG)
16 S S S R R (inhA)
17 S S S R R (katG) INH-MODS resistant on day 30
18 S S S R R (inhA)
19 S S S R R (inhA)
20 S S S R None
21 S S S R R (inhA)
22 S S S R R (inhA)
23 S S S R R (katG)
24 S S S R None
25 S S S R R (katG)
rpoB Sequencing was done for one isolate which failed to amplify for MAS-PCR
25/300 isolates (8.3%) had discrepant DST results between MODS and LJ for INH or RIF. R: resistant, S: sensitive, blank (−): no PCR product, blank cells:
concordance results between MODS and LJ therefore MAS-PCR was not attempted
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identified in rpoB.
Of 62 isolates with INH resistance by DST-LJ, 17 iso-
lates were INH-susceptible by MODS (Table 3 and Table
2). Of these 17 isolates, resistance mutations in katG and
inhA promoter genes were detected in 35.3% (n = 6/17)
and 47.1% (n = 8/17) of isolates, respectively. Three iso-
lates (17.6%, n = 3/17) were wild type by MAS-PCR.
Therefore, we concluded that 14/17 isolates were truly
INH resistant due to the confirmed presence of resistance
mutations. For the remaining 3 isolates we were unable to
confirm/exclude resistance since INH resistance confer-
ring mutations may be present outside the MAS-PCR tar-
get sites.
Twenty-two isolates with INH results discrepant
between DST-MODS and DST-LJ were repeated by DST-
MODS for INH at a lower concentration (0.1 μg/ml
instead of 0.4 μg/ml) because we hypothesised the 0.4 μg/
ml concentration may be missing low-level INH resistant
isolates since a recent meta-analysis [8] suggests increased
sensitivity of the 0.1 μg/ml INH concentration for MODS.
Eighteen (81.8%, n = 18/22) samples were culture negative
on MODS (smear results were negative for 13 samples,
scanty for one sample and 1+ for 4 samples). Therefore,
DST results for these samples were not available. The
repeat results of the remaining 4 isolates were completely
accordant with those of DST-LJ and MAS-PCR; two iso-
lates converted from resistant to susceptible and the
remaining two converted from susceptible to resistant.
The latter two isolates carried a mutation in the inhA pro-
moter region detected by MAS-PCR.
Analysis of samples with one positive control by DST-
MODS (DST-MODS results were recorded as
uninterpretable)
Thirty-two DST-MODS samples with one positive control
(Figure 1) were analyzed separately. Of which, 21.9% (n =
7 / 3 2 )w e r en e g a t i v eb yb o t hM G I Ta n dL Jc u l t u r ea n d
78.1% (n = 25/32) were positive by either MGIT or LJ cul-
ture. Data from routine testing showed that 96% of these
samples (n = 24/25) were negative by direct smear and
only one sample had a positive smear result (scanty result).
Time to detection (Median time in days)
Time to detection (positive) for TB diagnosis
Time to positive was recorded as the duration of time
from sample inoculation to positive result available in
days. For 327 samples positive by both MODS and
MGIT, the turn-around time of MODS was 9 days (IQR:
7-11 days) while it was 11 days (IQR: 7-13 days) for
MGIT. Compared to MGIT, the MODS results was avail-
able faster in 182 (56%), at the same time in 45 (14%) and
slower in 100 (31%) samples. The time to positive of
MODS was significantly faster than that of MGIT (P <
0.001) (Figure 3).
Time to DST result available
Time to DST result available was defined as the period of
time from sample inoculation to DST result available, in
days. For DST-MODS, this duration was exactly the
same as the time to positive by MODS culture (median =
9 days). For DST-LJ, this time was the sum of time to
positive of MGIT or LJ culture (a median of 11 days) and
performing DST-LJ (42 days). Therefore, the median
total turn-around time of DST-LJ was 53 days which was
much slower than DST-MODS.
Contamination
Contamination with fungi and cross-contamination were
analyzed for all 709 samples.
Contamination of MODS culture
The initial fungal contamination rate was 0.6% (n = 4/
709). No re-decontamination and re-culture on MODS
were attempted for contaminated MODS because of the
limited volume of MODS culture (1 ml). Three samples
were cross-contaminated with H37Rv,t h ep o s i t i v ec o n -
trol isolate used in this study and seven samples were
suspected of cross-contamination between samples, gen-
erating a maximum possible cross-contamination rate of
1.4% (n = 10/709).
Contamination of MGIT and LJ
The final fungal contamination rates of MGIT and LJ
were 0.7% (n = 5/709) and 0.6% (n = 4/709), respec-
tively. Four samples were contaminated for both MGIT
and LJ. Cross-contamination by MGIT and LJ was not
determined.
Discussion and conclusion
Our data shows that MODS is a sensitive and rapid
method for diagnosis of TB and MDR-TB. Although the
TB detection rate of MODS (50.5%) was not signifi-
cantly different from MGIT (51.6%, p =0 . 8 )a n dL J
(44.4%, p = 0.2), MODS was faster than MGIT with a
median time to detection of 9 days vs 11 days in sam-
ples positive by both methods.
Table 3 Analysis of MAS-PCR in 62 isolates with INH
resistance by proportional DST method, in relation to
DST/MODS results
MAS-PCR
DST/
MODS
KatG inhA KatG and
inhA
WT Indefinite Total
Resistant 33 03 01 07 01 45
Sensitive 06 08 00 03 00 17
All
strains
39 11 01 10 01 62
Of 17 isolates with INH sensitive by DST/MODS, 8 isolates (47.1%) had a
mutation on inhA promoter gene and 6 isolates (35.3%) carried amutation on
katG gene
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Page 8 of 11For MDR detection, the turnaround time strongly
favored DST-MODS (9 days) over DST-LJ (53 days).
The agreement, sensitivity, specificity, PPV and NPV of
DST-MODS against DST-LJ for detection of MDR-TB
isolates were 99%, 77.8%, 99.7%, 87.5% and 99.3%,
respectively. The low PPV for MDR detection may be
due to the low MDR-TB prevalence in the study popula-
tion (3.8% as reported in this study by the gold standard
DST-LJ method).
The sensitivities in detection of INH and RIF resistance
in our study were lower than those from the study of
Moore at el (72.6% vs 84.6% for INH and 72.7% vs 100%
for RIF) [15] although both studies used the same INH
concentration (0.4 μg/ml) and RIF concentration (1 μg/
ml). These concentrations have been recommended in the
MODS guidelines from the MODS development team in
Peru [30]. However, a recent meta-analysis published after
completion of this study concluded that the sensitivity of
INH-resistance detection was higher with a concentration
of 0.1 μg/ml without loss of specificity [8]. To address this
issue, we attempted to repeat DST-MODS and performed
MAS-PCR for 26 isolates with discrepant results between
DST-MODS and DST-LJ for INH and RIF.
For INH discrepant isolates, we found that 8/17 (47%)
isolates susceptible by DST-MODS but resistant by DST-
LJ carried mutation on inhA promoter region (Table 2
and Table 3). Previous studies have shown that inhA pro-
moter mutation is associated with low-level phenotypic
INH resistance (0.2 μg/ml) [31]. We attempted to repeat
DST-MODS for INH at 0.1 μg/ml concentration for all of
these 8 processed samples but only 2 samples were re-
identified as INH resistant. The remaining samples were
negative by MODS culture due to low bacterial load. This
is a limitation of this technique. Recently, Mello et al.
found that the sensitivity of DST-MODS for detection of
INH resistant isolates increased to 96.7% if INH 0.1 μg/ml
was used for the MODS assay [32]; and a similar conclu-
sion was reported from a meta-analysis [8]. This review
supported the use of INH 0.1 μg/ml for DST-MODS and
our data also supports the conclusion that the use of
0.4 μg/ml reduces sensitivity in comparison with conven-
tional DST. The clinical applicability of these concentra-
tions has not been determined. It is possible that a
low-level resistance to INH as defined by current in vitro
breakpoints may not translate to clinical resistance.
Further research is required to clarify the appropriate
management of these patients.
After resolving discrepant results between DST-MODS
and DST-LJ for RIF for 4 isolates (Table 2) by repeated
DST-MODS, MAS-PCR and rpoB sequencing, the final
sensitivity of DST-MODS for detection of RIF was 77.8%
(n = 7/9). However, this sensitivity is still lower than pre-
vious studies [15,32] although the number of RIF resistant
isolates in this study was small leading to wide 95% confi-
dence intervals on the sensitivity estimate (39-93%).
For 25 isolates with discrepant DST results between
DST-MODS and DST-LJ for INH or RIF (Table 2), 20
isolates were susceptible by DST-MODS for either INH
Figure 3 Time to positive of MODS culture and MGIT culture. In 327 samples positive by both MODS and MGIT, the turnaround time of
MODS and MGIT were 9 days (IQR: 7-11 days) and 11 days (IQR: 7-13 days), P < 0.001
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Page 9 of 110.4 μg/ml or RIF 1 μg/ml but resistant by DST-LJ. One
probable explanation is that the bacterial load present in
processed samples was not equally aliquoted into each of
4 wells of DST-MODS due to the clumping characteristic
of M. tuberculosis. It is possible higher bacterial concen-
trations were present in control wells than in the drug-
containing wells because processed samples were ali-
quoted into control wells first and then the drug-contain-
ing wells; and therefore cording formation was detected
earlier in control wells than in the drug-containing wells
if the isolate was resistant. As a result, at the reading
time, growth was seen in control wells but not in drug-
containing wells and this isolate was determined as a sus-
ceptible isolate by DST-MODS. The clumping of bacilli
may be the main factor leading to only a single positive
control well for 32 samples in our study. Samples with
low bacterial load (smear negative, smear scanty and
smear 1+) are more likely to result in inconsistent results
by direct DST-MODS due to unequal aliquoting.
The only equipment needed to perform the MODS
assay are an inverted microscope, tissue culture plate and
consumables, biological safety cabinet and incubator. The
technical competence required is aseptic technique and
microscopy skills, National TB Programmes applying
smear already have a workforce of experienced microsco-
pists. A commercial MODS plate (TB MODS kit™)h a s
been developed by Hardy Diagnostics, USA in collabora-
tion with PATH and is under evaluation. MODS is appro-
priate for screening for MDRTB in high burden countries
w h e r es u c ht e s t sa r eu r g e n t l yn e e d e d .
MODS meets many criteria for an MDR TB diagnostic
test applicable for high-burden settings; it is rapid, low-
cost and accurate and can be performed without the
need for biological safety level 3 laboratories (if the plate
is not opened after inoculation). Therefore, MODS is an
alternative method for rapid MDR-TB screening in
these settings. Recently, wide application of MODS in
resource-constrained settings has been endorsed by
WHO [9]. However, an international standard operating
procedure and a quality assurance system accredited by
WHO should be developed to standardize and maintain
accuracy.
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